Life Sciences Litigation – One Drug, Two Playbooks: Coordinating Hatch-Waxman Litigation and EPO Oppositions
Event summary
This webinar will focus on the strategic coordination of US Hatch-Waxman litigation and European Patent Office (EPO) opposition proceedings using a practical, scenario-based walkthrough of a hypothetical drug and patent portfolio. Key topics will include:
- Examining the key differences in legal standards, procedures and risks that innovators and challengers face on each side of the Atlantic
- Exploring how positions taken, and decisions made, in Hatch-Waxman litigation or EPO oppositions could influence parallel strategies in the other jurisdiction
- Reviewing issues such as the timing of patent challenges, estoppel considerations and discovery in US litigation versus the more document-driven EPO process
Speakers
- Betsy Flanagan – Partner, Cooley
- Tanya Heare-Rowlands – Special Counsel, Cooley
For more information, please email Megan Senerchia.
Related Contacts
This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as "Cooley"). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction, and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. When advising companies, our attorney-client relationship is with the company, not with any individual. This content may have been generated with the assistance of artificial intelligence (Al) in accordance with our Al Principles, may be considered Attorney Advertising and is subject to our legal notices.